BACKGROUND: DNA repair gene polymorphisms could alter DNA repair capacity and therefore associate with @entity5 sensitivity to radiochemotherapy. This study assessed excision repair cross-complementing group 1 ( @entity11833 ) @entity5359 and @entity20319 ( @entity20319 ) @entity61532 single-nucleotide polymorphisms in esophageal @entity1 for an association with sensitivity to radiation and chemotherapy. METHODS: Esophageal squamous cell @entity189 @entity1 (n = 118) who relapsed after surgery were enrolled for assessment of @entity11833 @entity5359 and @entity20319 @entity61532 polymorphisms by direct DNA sequencing. RESULTS: The response rate of treatments was 48.30%: 14 complete response (CR, 11.86%), 43 partial response (PR, 36.44%), 49 @entity66 ( @entity66 , 41.53%), and 12 @entity74 ( @entity74 , 10.17%). @entity11833 @entity5359 was significantly associated with treatment response (C/T vs. C/C + @entity1619 , odds ratio [OR] = 6.035, 95% confidence interval [CI]: 2.114-17.226, P = 0.001) after adjusting for other clinicopathological factors. @entity1 carrying the C/T genotype had significantly prolonged @entity1349 ( @entity1349 ) compared with C/C and @entity1619 (median @entity1349 43.00 vs. 27.00, P = 0.027). Multivariate Cox regression showed that a response was only an independent prognostic factor for @entity1349 (CR + PR vs. @entity66 + @entity74 , HR = 0.471 95% CI 0.269-0.826, P = 0.009). Grade III and IV adverse events occurred in 12 of 118 @entity1 (10.17%). Only concurrent radiochemotherapy significantly increased these adverse events (OR = 26.529, 95% CI 2.312-304.389, P = 0.008). CONCLUSION: @entity11833 @entity5359 could be a predictive factor for the response to radiotherapy and chemotherapy, but not a prognostic factor for @entity1349 in @entity418 @entity1 after surgery.

DNA repair gene @entity11833 XXXX polymorphism predicts sensitivity of recurrent @entity418 to radiochemotherapy in a Chinese population.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity11833 :: ('2067', 'Gene') :: ['ERCC1'] @entity1619 :: ('MESH:D015458', 'Disease') :: ['T/T'] @entity5359 :: ('c|SUB|C|118|T', 'DNAMutation') :: ['C118T'] @entity66 :: ('MESH:D004194', 'Disease') :: ['SD', 'stable disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity20319 :: ('7515', 'Gene') :: ['XRCC1', 'X-ray cross-complementing group 1'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity61532 :: ('c|SUB|G|399|A', 'DNAMutation') :: ['G399A'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity5359 :: (c|SUB|C|118|T,DNAMutation) :: ['C118T']
